Takeda Reports Long-Term Safety and Efficacy Results of its Dengue Vaccine Candidate

Shots:

• The P-III TIDES study involves assessing two doses of TAK-003 (0.5mL, SC on day 1 & 90) vs PBO to prevent laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 20,000+ children and adolescents
• Results: @36mos. after the second dose, 62.0% VE against VCD; 65.0% VE in seropositive; 54.3% VE in seronegative individuals. TAK-003 also demonstrated 83.6% VE against hospitalized dengue, with 86.0% VE in seropositive & 77.1% VE in seronegative individuals
• The regulatory filing in the EU and dengue-endemic countries is under progress while the company plan to regulatory application in the US in late 2021

Click here to­ read full press release/ article | Ref: Takeda | Image: GENEOnline